Dr. Reiman is Executive Director of Banner Alzheimer’s Institute, Chief Executive Officer of Banner Research, Professor of Psychiatry at the University of Arizona, University Professor of Neuroscience at Arizona State University, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research Center (ADRC), and a leader of the Alzheimer’s Prevention Initiative (API). He is also a co-founder and advisor to ALZPath, a company involved in the development of blood tests for Alzheimer’s and related diseases, and Chairman of the Board of the Flinn Foundation. A psychiatrist and brain imaging researcher by background, his interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and the establishment of new models of research collaboration and clinical care. He is an author of nearly 700 publications, a principal investigator of several large NIH grants, other state and foundation grants, and contracts, a former member of the National Advisory Council on Aging (NIA Council), and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, prevention, and study of Alzheimer’s disease. He and his colleagues seek to find and support the approval and accessibility of effective Alzheimer’s prevention therapies within the next few years.